Introduction
Rheumatic diseases affect multiple organs and are characterised by chronic inflammation which is maintained by intrinsic triggers 1 . Although this group of diseases is heterogeneous with respect to the molecular aetiology, many clinicial manifestations as well as key therapeutic targets overlap. When poorly controlled, rheumatic disorders may deteriorate with severe multi-organ involvement. In addition, the presence of these diseases may complicate the course of initially unrelated conditions by compromising organ and tissue function 2 . Potential risk factors for morbidity and mortality in patients with rheumatic diseases may also include immunosuppressive and other side-effects of treatments used for these conditions.
Previous investigations into the outcome of patients with rheumatic diseases treated in intensive care units (ICU) reported an increased mortality compared to intensive care patients without rheumatic diseases 3, 4 . Mortality rates in the ICU of up to 55% have been documented for mixed patient populations with various rheumatic diseases 4 . The mortality in some studies substantially exceeded predicted mortality 5 . Several studies reported significant problems with the predictive accuracy of the Acute Physiology and Chronic Health Evaluation II (APACHE II) score in this patient group 3, 8 . In a large cohort study, survival of patients with rheumatic disorders admitted to ICU was associated with the degree of organ dysfunction and specific features of the underlying rheumatic disease 6 . Thus, to date, the concomitant presence of a rheumatic disease is considered a risk factor for decreased survival in ICU patients 7 . However, none of the previous studies had an age-and gender-matched control group, despite differences in the distribution of these characteristics between patients with and without rheumatic diseases. Most of these studies did not include a control group at all 4,7-11 . Therefore, the role of rheumatic disorders in the prognostication of ICU patients remains to be defined.
The past decade has seen a substantial improvement in the management of rheumatic diseases due to novel treatment strategies 12 . Also, new data show a marked decrease in the mortality of patients with rheumatic diseases when admitted with a critical illness 13 . A recent report indicated that the presence of an autoimmune disease is no longer a significant independent prognosticator for patients admitted to hospital for unrelated conditions 14 .
The aim of this study was to compare clinical and outcome characteristics of a large cohort of patients with and without rheumatic diseases admitted to our medical ICU and to assess potential prognosticators.
Materials and methods
This observational study used a database that includes all admissions to the Medical ICU at the Hadassah Hebrew University Medical Center in Jerusalem, Israel. Patients' data were collected prospectively at the time of treatment in the medical ICU. Waiver for informed consent for including patient information in the database was provided by the institutional review board (Approval number 200-03.11.06, Hadassah Hebrew University Medical Center).
The records of all patients (n=4020) admitted to the medical ICU between 1 April 2003 and 30 June 2014 were screened for the presence of a rheumatic disease during admission. The diagnosis of a rheumatic disease was by standard criteria for these conditions during the period of data collection and coded according to ICD-9. A control group of patients without rheumatic disease was extracted from the patient population in the database during the same period. First, the total population of potential controls was stratified according to age and gender. Thereafter, controls were randomly chosen from these subgroups. The numbers of individuals to be extracted from each subgroup were defined by the age and gender frequencies within the population of patients with rheumatic diseases. Length of survival was determined from either hospital files or from Ministry of Interior records.
Statistical analysis was performed using SPSS version 19 (IBM, NY, USA). Continuous variables are presented as means and standard deviation (SD) for normally distributed data and as medians and ranges for all other data. Comparison of normally distributed continuous variables between groups was performed using Student's t-test. The Wilcoxon signed rank test was used for comparing other continuous variables. Comparison of categorical values was performed using the chi-square test. Logistic regression analysis was performed to model prognostic factors influencing hospital outcome in patients with rheumatic conditions. The logistic regression model was developed using demographic and clinical data such as gender, age, APACHE II score, need for ventilation, need for renal replacement therapy, presence of septic shock, acute respiratory distress syndrome (ARDS), use of inotropic support, and chronic immunosuppression. Logistic regression analysis was performed on parameters that were significantly associated with mortality. The area under the receiver operating characteristic curve (AUROC) for the Cox regression analysis was calculated including the 95% confidence interval (CI). Kaplan-Meier analysis was performed comparing longterm survival between groups. Cox regression analysis was used to evaluate parameters influencing long-term outcome.
Survival was censored at the last date for follow-up, i.e. 1 November 2015.
Results
One hundred and thirty-eight consecutive patients with rheumatic diseases and 831 age-and gender-matched controls without rheumatic disorders were included in this study. Fifteen of the patients with rheumatic conditions (10.9%) had their disease diagnosed after ICU admission. Ninety-five patients with rheumatic conditions (68.8%) were on immunosuppressive medication prior to ICU admission with the majority (82 patients) treated with steroids. The incidence of specific rheumatic conditions in our study Table 2 . There was no significant difference between the two groups with respect to disease severity scores. When compared to all patients in our database without rheumatic diseases (and not just the control group) the mean age of patients with rheumatic diseases was younger (55.3 ± 19.3 versus 60.7 ± 19.9 years, P=0.002) and there were more female patients (69.6% versus 43.7%, P <0.0001). Table 3 shows the admission diagnoses of the group with rheumatic diseases and the control group. Infections and respiratory failure constitute the most frequent diagnoses for both groups. Pneumonia was more prevalent in patients with rheumatic diseases compared to controls. However neurological and metabolic diagnoses were more common in the control group. Blood cultures were obtained from all patients with rheumatic diseases and 8.7%, 12.3% and 1.45% tested positive for Gram-positive, Gram-negative and fungal agents, respectively. Table 3 also shows the frequencies for respiratory, cardiovascular and renal support therapies in patients with and without rheumatic diseases. Apart from a lower rate of mechanical ventilation in patients with rheumatic diseases, there were no significant differences between the two groups. There was no significant difference between patients with rheumatic diseases and controls in length of stay in ICU or hospital ( Table 2 ) nor in mortality in the ICU, in the hospital or after 180 days (Table 3 ). We checked for trends in mortality over time for patients with rheumatic conditions by comparing the first 69 patients (admitted 2003 to 2009) with the other 69 patients admitted later (2009 to 2014). There was no significant difference between these two subgroups for ICU or hospital mortality.
There was a significant difference in APACHE II score between survivors and non-survivors for the patients with rheumatic diseases, as well as for the control group, both for mortality in the ICU and in the hospital ( Table 4 ). The ratio between observed mortality and mortality predicted by the APACHE II score (standardised mortality ratio [SMR]) was 77.7% for patients with rheumatic diseases and 70% for the control group (P=0.2).
Kaplan-Meier analysis for survival after ICU admission did not show a significant difference between patients with or without rheumatic diseases (Figure 1 , on next page). Cox regression analysis revealed that the parameters associated with long-term mortality for the whole cohort were age (hazard ratio 1.01 for each increase in year, P <0.0001), gender (hazard ratio 0.76 for female gender, P=0.012), use of inotropes (hazard ratio 1.8, P <0.0001) and APACHE II score (hazard ratio 1.06 for each point, P <0.0001). The presence of a rheumatic disease was not associated with long-term mortality (P=0.15). Cox regression of the cohort of patients with rheumatic diseases showed that parameters associated with long-term mortality were age (hazard ratio 1.02 for each increase in year, P=0.07), gender (hazard ratio 0.55 for female gender, P=0.035) and APACHE II score (hazard ratio 1.07 for each point, P <0.0001). Logistic regression analysis for hospital outcome demonstrated that the requirement for inotropic/vasopressor therapy and the APACHE II score were the most significant predictors of death in hospital for patients with rheumatic diseases. AUROC for this model was 0.91 (Table 5) .
Patients with systemic lupus erythematosus (SLE) and vasculitis constituted the two largest subgroups of patients with rheumatic diseases (Table 1) . For these subgroups (SLE versus vasculitis) age (43.9 +/-15.3 years versus 59.6 +/-18.9 years; P=0.0001) as well as gender frequency (86.5 versus 62.9% females, P=0.002) differed significantly. APACHE II and Sequential Organ Failure Assessment (SOFA) scores, however, were not significantly different. There was a significantly increased mortality for vasculitis patients in hospital compared to patients with SLE (40.0% versus 18.9%, P=0.047). There was no significant difference between these two subgroups with respect to organ support (data not shown).
Discussion
This study investigated clinical and outcome characteristics of patients with systemic rheumatic diseases admitted to a medical ICU in a tertiary care centre. Our main findings are that the outcome for patients with a diagnosis of a rheumatic disease is not significantly worse than comparable ICU patients who do not have a diagnosis of a rheumatic disease. The SMR was similar for patients with and without rheumatic diseases. A high APACHE II score and a requirement for the use of inotropes/vasopressors were the most significant predictors of hospital mortality in the group of patients with rheumatic diseases.
Previous reports on patients with rheumatic diseases have been characterised by a high mortality rate that varied substantially between studies 4 . In contrast to previous studies 15 , we have included age-and gender-matched controls without rheumatic diseases from the same ICU to correct for the different distributions of age and gender in comparison to the general ICU patient population. For all ICU patients, characteristics were prospectively recorded in a registry maintained by a single database manager to ensure robustness and consistency over a prolonged period of time. Moreover, measures of mortality in this database were not influenced by subjective decisions about treatment withdrawal, as this approach is not legal in Israel. Of note, the oldest patients in the two groups of our study were 93 and 102 years.
The demographic and clinical characteristics of our patients with rheumatic diseases were very similar to the data from a recently published retrospective study from France 11 . That investigation involved 363 patients with rheumatic diseases from ten medical ICUs and thus is the largest study on this topic so far. However, it did not include a control group and thus could not make conclusions about the specific impact of rheumatic diseases on mortality. The French study as well as our study involved predominantly female patients. The median age was 59 and 57 years in the two studies, respectively. SLE and vasculitis were the largest subgroups in both studies, each of them constituting approximately a quarter of all patients. Infections dominate the list of reasons for ICU admission, with Gram-negative bacteria being more frequently detected than Gram-positive in both studies. The SOFA scores were also similar in the two studies. ICU mortality for patients with rheumatic diseases was 21% in the French study, which was similar to the mortality in our study (23%). Importantly, the presence of shock, i.e. the need for vasopressors/inotropes, and the disease severity score were the two most important prognosticators of mortality in both the French study and our study. The similarities between the patient populations strongly suggest that the additional findings in our study with respect to prognosis could be applicable to a more general setting of intensive care practice. We did not detect a significant difference in mortality between ICU patients with rheumatic diseases and ageand gender-matched controls for various time points (ICU, hospital and 180 day mortality). These findings emphasise the current trend towards a better prognosis for patients with rheumatic diseases admitted to hospital, which differs from that of historical cohorts 13, 14, 16 . This improvement appears to be due to the routine use of efficient immunomodulatory strategies for these patients 12 . Of note, recent reports could not demonstrate a negative impact of these newer treatment regimens on survival in this patient population when admitted to intensive care 7, 16 . These data challenge the historical perception that the presence of a rheumatic disease is of itself a negative prognosticator in ICU patients. However, studies of patients with specific autoimmune diseases admitted to ICU with a particular problem, such as granulomatosis with polyangiitis and respiratory failure, are needed to further assess patient groups with an apparently higher mortality 17, 18 . A recent study of mortality following myocardial infarction demonstrated an increased risk for patients with rheumatic diseases 19 . There are also higher rates of death in SLE patients 20 . However, Han et al 21 documented a similar outcome for ICU patients with and without SLE and infections indicating that the mortality differences described previously might not exist in critically ill patients today.
Faguer et al 6 reported on a cohort of patients with rheumatic diseases and suggested a role for the underlying disease on ICU outcome. A larger multicentre study could not confirm this finding 11 . Also in our study, there was no significant difference in disease severity scores or the need for organ support between the two largest subgroups, i.e. patients with SLE or vasculitis. However, patients with vasculitis had a higher mortality in hospital compared to patients with SLE. We did not further analyse other subgroups in our study due to their small size.
Prognostication of outcomes remains a challenge in ICU. The validity of the APACHE II score for predicting mortality in patients with rheumatic diseases has been questioned by several studies 5, 8, 22 . However, our data indicate that the APACHE II score is a valid prognosticator of mortality in patients with rheumatic diseases. APACHE II scores as well as SMRs did not differ between patients with and without rheumatic diseases in our ICU. The presence of a rheumatic disease may well be a risk factor for organ failure. However, we did not find a significant increase in organ support requirements in patients with rheumatic diseases compared to matched controls. The need for inotropes/vasopressors as a predictor for mortality in patients with rheumatic diseases has been documented in various studies 11, 20, 23 . In our study, logistic regression analysis for hospital mortality confirmed this finding for the patient population in a medical ICU.
The strength of this study is the comparison with an age-and gender-matched control group. However, it is not a prospective interventional investigation. Thus, causal relationships, such as that between specific immunosuppressive drugs and outcome, could not be detected. In addition, the relatively low incidence of rheumatic diseases required a long sampling period that may have resulted in yet-undetected variations in treatment. Moreover, small differences in outcome could have been missed due to the small cohort of patients.
In conclusion, our study showed that patients with a diagnosis of a rheumatic condition admitted to an ICU do not do significantly worse than patients without such a diagnosis. A high APACHE II score and the need for inotropes/ vasopressors accurately predicted the hospital outcome in this patient group.
